Pfizer Secures Agency Review of Two UniQure Hemophilia Patents

Nov. 18, 2021, 7:20 PM

The Patent Trial and Appeal Board will review two gene therapy patents that Pfizer Inc. alleges don’t contain new ideas.

Pfizer told the board U.S. Patent Nos. 9,982,248 and 10,465,180 owned by UniQure Biopharma B.V. should be canceled. The patents cover a gene therapy involving nucleic acids that encode for a variant of a human protein called factor IX to treat hemophilia B.

The board agreed in three separate decisions that Pfizer has shown a reasonable likelihood it will prove that the patented inventions were disclosed a decade earlier by scientists at the University of North Carolina or that several ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.